President Donald Trump announced new agreements with nine pharmaceutical companies to reduce the prices of certain drugs. This move aligns with his administration’s health care agenda as the midterm elections approach.
The companies committed to cutting costs via the Most Favored Nation program. This initiative aims to align US drug prices with lower rates in other nations, benefiting American consumers.
“We’ve achieved a big win for American households,” Trump stated in the Oval Office, emphasizing the program’s impact on reducing healthcare costs.
These agreements serve as a part of Trump’s strategy to showcase his administration’s focus on healthcare reforms, targeting voter concerns about drug affordability.